This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 3.54% and -4.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
by Zacks Equity Research
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 7.26% and 17.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump
by Zacks Equity Research
Flexion Therapeutics (FLXN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
by Zacks Equity Research
Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.
Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up
by Zacks Equity Research
Flexion Therapeutics (FLXN) announced that its non-opioid intra-articular injection for treating knee pain has received FDA approval.
Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher
by Zacks Equity Research
Flexion Therapeutics (FLXN) shares rose more than 10% in the last trading session, amid huge volumes.